How the hell did he land here? Will we ever know? I don't care that much if I don't ever know. I care about my investment, first and last, and I will lash out at him if he's twisting facts.
I spend a few minutes responding to your bilge and you think I do not have a life? I got a lot of things done today in my busy life. I am an investor in this company and am concerned about your constant denigration, lying, misrepresentation, and innuendo about this company with little logic or reason. I want to spend as little time as possible in interactions with you, but I do need to respond briefly and refute your bilge. You agree, (right?) with terry (yourself) that the relapse rate in the 112 trial was 30%? I do not expect you to respond because I know you are #$%$.
Oh sure, you are not terry. Well, what do you, as his lackey, think of his twisting of facts about the relapse rate in the 112 trial. I'm sure you're OK with it because YOU ARE TERRY. Defend his thesis, if you are not terry. I dare you!
Excellent! I'm waiting for a rebuttal by the freak clownboy. I'm sure it won't involve anything like reasoning or math. I especially love his prescient calls after the fact. How dumb can one be?
You lying sack of !@#$! The relapse in the 112 trial was 2/14 or 14%. Lewis , when he said 30% was referring to historical relapse rates for NTM with other treatments. But you probably knew this. Lewis and the analyst were both impressed by the durability of Arikayce treatment. This is absolute proof that you are a perverse twister of facts and why anyone like zake1 would have any regards for you is a mystery to me, unless zake1 is duplicitous or perhaps even YOU.
Hey clownboy, where are the CF patients who develop Pseudomonas strains resistant to Tobramycin gonna go? To off-label Arikayce at NTM prices. Get it? FRom 1999- 2012 there was an 85% increase in resistance to TOBI per FDA advisory panel US-FDA- AIDAC for TOBI-Podhaler- September 2012. Check the Investor Presentation.
You big dummy! The relapse in the 112 trial was 2/14 or 14%. Lewis , when he said 30% was referring to historical relapse rates for NTM with other treatments. But you probably knew this. Lewis and the analyst were both impressed by the durability of Arikayce treatment. You must think we're stupid. You suck at bashing.
As many of you may know, Franklin Street Partners just down the road from me in Chapel Hill has been a long-time holder of INSM, probably before the iPlex settlement like a lot of us. They always report their holdings soon after the end of the quarter and thus provide a nearly up-to-the-minute reveal of their stance. They must be sitting on gains at least as large as mine, and yet they appear to be holding their entire position for yet larger expected gains. This as a good sign.